Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, welcomed Mrs Kemi Badenoch, MP for Saffron Walden, to its offices at Chesterford Research Park.
Arecor’s Chief Executive Officer, Dr Sarah Howell and Chief Financial Officer, Susan Lowther, met with Mrs Badenoch MP, to discuss the current climate for small companies in the UK healthcare industry.
They covered a wide range of topics from the importance of funding, both Government grant funding and R&D tax credits, investment from VCTs and EIS, innovation in the sector and the need for science parks, as well as the Government’s thought around tackling diabetes, one of Arecor’s proprietary products in development.
Mrs Badenoch MP, said: “I enjoyed learning so much about Arecor’s business and their contribution to our local economy. Their work in taking existing drugs like insulin and enhancing them to improve results for patients, is groundbreaking. I was also glad to hear that Arecor found Chesterford Research Park to be one of the best places to attract talent in research and development - vindication of the council’s decision to invest in the Park. Arecor has a very constructive relationship with the Government especially regarding research funding and I will continue to support them in this whenever possible.”
Dr Sarah Howell, Chief Executive Officer of Arecor, added: "It was fantastic to meet with Mrs Badenoch and discuss life as an SME. She was very supportive, taking time to understand our business and the challenges we face. We look forward to building a positive, active relationship and to see her support the issues facing our industry in parliament."
For more information, please contact:
Notes to Editors
About Arecor (www.arecor.com)
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
- Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
- Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
- Stable aqueous glucagon for emergency and artificial pancreas use, and
- A series of undisclosed pre-clinical programmes.
In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.